rAAV-EF1a
Recombinant adeno-associated viruses (rAAVs) utilizing the EF1α promoter are designed for robust, constitutive expression of transgenes in a wide range of cell types. The elongation factor 1 alpha (EF1α) promoter is derived from a highly conserved eukaryotic gene involved in protein synthesis, making it an excellent choice for high and stable expression across various experimental models.
Features of rAAV-EF1α
- Broad Tropism:
- The EF1α promoter drives transgene expression in multiple cell types, including neurons, glia, muscle, and other somatic cells.
- Effective in both dividing and non-dividing cells.
- Species Compatibility:
- Functional across a broad range of mammalian species, including rodents, primates, and humans.
- Stable and Long-Term Expression:
- Supports sustained expression in vivo, ideal for chronic studies.
- Moderate to High Expression Levels:
- Provides strong expression, though generally lower than the CMV promoter, with reduced risk of promoter silencing in certain tissues.
Applications of rAAV-EF1α
- Gene Therapy:
- Delivery of therapeutic genes for a wide range of diseases, such as muscular dystrophies, neurodegenerative disorders, and retinal diseases.
- Neuroscience Research:
- Expression of optogenetic and chemogenetic tools for circuit manipulation.
- Delivery of fluorescent reporters (e.g., GFP, RFP) for imaging and cell tracking.
- CRISPR/Cas9 and Genome Editing:
- Delivery of gene-editing components, such as Cas9, guide RNAs, or base editors, in diverse cell types.
- Molecular and Cellular Studies:
- Overexpression of proteins or knockdown of genes to study their roles in biological processes.
- Use in stem cell research and organoid models.
- Animal Models:
- Generating transgenic animal models for disease research.
rAAV-EF1α is a versatile and reliable gene delivery system suitable for a wide range of research and therapeutic applications. Its broad applicability and stability make it a preferred choice for experiments requiring constitutive transgene expression in diverse cell populations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|